
Zerlasiran Leads to Significant Lipoprotein(a) Reductions at 36 Weeks
Following these positive 36-week results, Silence Therapeutics plans to announce 48-week results of the ongoing ALPACAR-360 study in Q2 of 2024.
Silence Therapeutics has released promising findings from the ongoing ALPACAR-360 phase 2 trial of zerlasiran, demonstrating a 90% median decrease in lipoprotein(a) (Lp[a]) at week 36.
The study involved 178 participants with baseline Lp(a) levels of 125 nmol/L or higher, putting them at significant risk for
According to a
“We are excited about the emerging phase 2 data, which are very consistent with phase 1 results and support a competitive profile for treating patients with high Lp(a),” said Steven Romano, MD, head of research and development at Silence Therapeutics. “We look forward to reviewing the 48-week data and advancing zerlasiran as a potential treatment to address this major unmet need in cardiovascular disease.”
Zerlasiran is wholly owned by Silence Therapeutics and works as a gene silencing therapy, aiming to temporarily stop the transmission of a particular gene's instructions that could lead to undesired outcomes. According to the
Silence Therapeutics wrapped up phase 1 of the study in August 2023 with 70 participants. In the
The 60-week ALPACAR-360 study is ongoing, and secondary endpoints will be assessed. These include examining changes in Lp(a) levels from baseline to 48 weeks (end of treatment period) and 60 weeks (end of the study), as well as assessing potential effects on other lipids/lipoproteins. Following these positive 36-week results, Silence Therapeutics plans to announce 48-week results of the ongoing ALPACAR-360 study in the second quarter of 2024.
References
1. Silence Therapeutics announces positive topline 36-week data from ongoing phase 2 study of zerlasiran in patients with high lipoprotein(a). News release. Silence Therapeutics. March 13, 2024. Accessed March 13, 2024. https://silence-therapeutics.com/investors/press-releases/press-releases-details/2024/Silence-Therapeutics-Announces-Positive-Topline-36-Week-Data-from-Ongoing-Phase-2-Study-of-Zerlasiran-in-Patients-with-High-Lipoproteina/default.aspx
2. Addressing a major unmet need in cardiovascular disease. Silence Therapeutics. Accessed March 13, 2024. https://silence-therapeutics.com/our-pipeline/zerlasiran/default.aspx
3. Silence Therapeutics completes enrollment in phase 2 study of zerlasiran (SLN360) in subjects with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events. News release. Silence Therapeutics. May 1, 2023. Accessed March 13, 2024. https://silence-therapeutics.com/investors/press-releases/press-releases-details/2023/Silence-Therapeutics-Completes-Enrollment-in-Phase-2-Study-of-Zerlasiran-SLN360-in-Subjects-with-Elevated-Lipoproteina-at-High-Risk-of-Atherosclerotic-Cardiovascular-Disease-Events/default.aspx
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.